Harvard Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Bruce Jackson from Benchmark Co. maintained a Buy rating on the stock and has a $3.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bruce Jackson’s rating is based on Harvard Bioscience’s recent announcement of surpassing revenue expectations for the second quarter, reporting approximately $20.4 million compared to the anticipated $18.8 million. This positive financial performance indicates strong operational execution and potential for continued growth.
Additionally, the company’s leadership transition, with John Duke stepping in as the new President and CEO, along with the appointment of two new independent directors, Rob Gagnon and Seth Benson, suggests a strategic direction that could further enhance shareholder value. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s future prospects.